Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 11.

Journal Article

Brandes, V, Scheffler, M., Kambartel, K., Ortiz-Cuaran, S., Scheel, A., Michels, S., Nogova, L., Fischer, R., Abdulla, D., Merkelbach-Bruse, S., Buettner, R., Sos, M. L. and Wolf, J. (2016). Targeting HER2-and MET co-amplification in patients with EGFR mutation resistant to EGFR-TKI therapy. Oncol. Res. Treat., 39. S. 172 - 173. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., Abdulla, D., Michels, S., Nogova, L., Brandes, V, Scheffler, M., Schaeffer, S., Scheel, A., Thurat, M., Vehreschild, M., Thomas, R., von Bergwelt-Baildon, M., Buettner, R. and Wolf, J. (2016). Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition. Oncol. Res. Treat., 39. S. 92 - 94. BASEL: KARGER. ISSN 2296-5262

Koleczko, S., Schaepers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Brandes, V., Abdulla, D., Ueckeroth, F., Thurat, M., Frank, R., Eisert, A., Bitter, E., Woempner, C., Gogl, L., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Ann. Oncol., 27. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Koleczko, S., Schapers, C., Scheffler, M., Ihle, M., Kostenko, A., Michels, S., Fischer, R., Nogova, L., Serke, M., Kaminsky, B., Benedikter, J., Bruemmendorf, T. H., Ficker, J. H., Lorenz, J., Schulte, C., Schulze-Olden, S., Brandes, V, Abdulla, D., Ueckeroth, F., Thurat, M., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2016). A comprehensive analysis of potentially targetable genetic aberrations and clinical findings in 821 patients with squamous-cell NSCLC - a comparison of NGM and TCGA LUSC data. Oncol. Res. Treat., 39. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Nogova, L., Fischer, R., Ueckeroth, F., Abdulla, D., Kron, F., Pauli, B., Kaminsky, B., Braess, J., Graeven, U., Grohe, C., Krueger, S. ORCID: 0000-0002-1658-5993, Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Kron, A., Riedel, R., Michels, S., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Ueckeroth, F., Schueller, M., Pauli, B., Grohe, C., Kaminsky, B., Braess, J., Graeven, U., Krueger, S., Nogova, L., Abdulla, D., Fischer, R., Heydt, C., Buettner, R. and Wolf, J. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF mutated lung cancer patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 247 - 248. BASEL: KARGER. ISSN 2296-5262

Kron, A., Riedel, R., Michels, S., Heydt, C., Fassunke, J., Merkelbach-Bruse, S., Scheffler, M., Fischer, R., Abdulla, D., Nogova, L., Ueckeroth, F., Pauli, B., Schueller, M., Serke, M., Koschel, D., Krueger, S., Grohe, C., Kambartel, K., Sebastian, M., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation tyrosine kinase inhibitors (TKI) and co-occurring mutations in ALK-positive NSCLC patients: results of the Network Genomic Medicine. Oncol. Res. Treat., 40. S. 219 - 220. BASEL: KARGER. ISSN 2296-5262

Manthou, M., Nohroudi, K., Moscarino, S., Rehberg, F., Stein, G., Jansen, R., Abdulla, D., Jaminet, P., Semler, O., Schoenau, E. and Angelov, D. N. (2015). Functional recovery after experimental spinal cord compression and whole body vibration therapy requires a balanced revascularization of the injured site. Restor. Neurol. Neurosci., 33 (2). S. 233 - 250. AMSTERDAM: IOS PRESS. ISSN 1878-3627

Michels, S., Plenker, D., Wagener, S., Scheffler, M., Nogova, L., Abdulla, D., Riedel, R., Bunck, A., Merkelbach-Bruse, S., Buettner, R., Sos, M. and Wolf, J. (2017). Loss of ROS1 G2032R resistance mutation upon chemotherapy treatment enables successful crizotinib rechallenge in a ROS1-rearranged NSCLC patient. Oncol. Res. Treat., 40. S. 232 - 233. BASEL: KARGER. ISSN 2296-5262

Riedel, R., Kron, A., Michels, S., Fassunke, J., Scheffler, M., Fischer, R., Nogova, L., Abdulla, D., Heydt, C., Ueckeroth, F., Pauli, B., Serke, M., Krueger, S. ORCID: 0000-0002-1658-5993, Grohe, C., Sebastian, M., Koschel, D., Kambartel, K-O., Zander, T., Buettner, R. and Wolf, J. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Ann. Oncol., 28. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041

Riedel, R., Plenker, D., Michels, S., Nogova, L., Abdulla, D., Scheffler, M., Fischer, R., Brandes, V., Heukamp, L. C., Scheel, A. H., Buettner, R., Sos, M. L. and Wolf, J. (2017). KIF5B-MET fusion genes are novel targets in NSCLC and show sensitivity to MET inhibition with crizotinib. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262

This list was generated on Thu Mar 28 19:32:06 2024 CET.